Found: 19
Select item for more details and to access through your institution.
Impact of Therapy in Patients with Hematologic Malignancies on Seroconversion Rates After SARS-CoV-2 Vaccination.
- Published in:
- Oncologist, 2022, v. 27, n. 4, p. e357, doi. 10.1093/oncolo/oyac032
- By:
- Publication type:
- Article
Pembrolizumab and Trastuzumab in High Tumor Mutational Burden and POLE-Mutated HER2-Positive Refractory Breast Cancer.
- Published in:
- Oncologist, 2022, v. 27, n. 4, p. 245, doi. 10.1093/oncolo/oyac027
- By:
- Publication type:
- Article
Joint-Predominant Rheumatic Complications of Immune Checkpoint Inhibitor Therapy in Patients with Thymic Epithelial Tumors.
- Published in:
- Oncologist, 2022, v. 27, n. 4, p. e353, doi. 10.1093/oncolo/oyac026
- By:
- Publication type:
- Article
Plasma Epstein-Barr Virus MicroRNA BART8-3p as a Diagnostic and Prognostic Biomarker in Nasopharyngeal Carcinoma.
- Published in:
- Oncologist, 2022, v. 27, n. 4, p. e340, doi. 10.1093/oncolo/oyac024
- By:
- Publication type:
- Article
Impact of Iron-Deficiency Management on Quality of Life in Patients with Cancer: A Prospective Cohort Study (CAMARA Study).
- Published in:
- Oncologist, 2022, v. 27, n. 4, p. 328, doi. 10.1093/oncolo/oyac005
- By:
- Publication type:
- Article
Efficacy of Infliximab Dose Escalation in Patients with Refractory Immunotherapy-Related Colitis: A Case Series.
- Published in:
- Oncologist, 2022, v. 27, n. 4, p. e350, doi. 10.1093/oncolo/oyac019
- By:
- Publication type:
- Article
Methadone as First-line Opioid for the Management of Cancer Pain.
- Published in:
- Oncologist, 2022, v. 27, n. 4, p. 323, doi. 10.1093/oncolo/oyab081
- By:
- Publication type:
- Article
Surrogacy Beyond Prognosis: The Importance of "Trial-Level" Surrogacy.
- Published in:
- Oncologist, 2022, v. 27, n. 4, p. 266, doi. 10.1093/oncolo/oyac006
- By:
- Publication type:
- Article
Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG).
- Published in:
- Oncologist, 2022, v. 27, n. 4, p. 255, doi. 10.1093/oncolo/oyac022
- By:
- Publication type:
- Article
Genetic Evaluation for Hereditary Cancer Syndromes Among African Americans: A Critical Review.
- Published in:
- Oncologist, 2022, v. 27, n. 4, p. 285, doi. 10.1093/oncolo/oyab082
- By:
- Publication type:
- Article
Evaluation of Tumor DNA Sequencing Results in Patients with Gastric and Gastroesophageal Junction Adenocarcinoma Stratified by TP53 Mutation Status.
- Published in:
- Oncologist, 2022, v. 27, n. 4, p. 307, doi. 10.1093/oncolo/oyac018
- By:
- Publication type:
- Article
Rh-Endostatin Plus Irinotecan/Cisplatin as Second-Line Therapy for Advanced Esophageal Squamous Cell Carcinoma: An Open-Label, Phase II Study.
- Published in:
- Oncologist, 2022, v. 27, n. 4, p. 253, doi. 10.1093/oncolo/oyab078
- By:
- Publication type:
- Article
Combining Analysis of Tumor-infiltrating Lymphocytes (TIL) and PD-L1 Refined the Prognostication of Breast Cancer Subtypes.
- Published in:
- Oncologist, 2022, v. 27, n. 4, p. e313, doi. 10.1093/oncolo/oyab063
- By:
- Publication type:
- Article
Three-Year Outcomes of a Phase II Study of Perioperative Capecitabine Plus Oxaliplatin Therapy for Clinical SS/SE N1-3 M0 Gastric Cancer (OGSG 1601).
- Published in:
- Oncologist, 2022, v. 27, n. 4, p. 251, doi. 10.1093/oncolo/oyab061
- By:
- Publication type:
- Article
Essentials of Multiomics.
- Published in:
- Oncologist, 2022, v. 27, n. 4, p. 272, doi. 10.1093/oncolo/oyab048
- By:
- Publication type:
- Article
Position Statement on the Diagnosis, Treatment, and Response Evaluation to Systemic Therapies of Advanced Neuroendocrine Tumors, With a Special Focus on Radioligand Therapy.
- Published in:
- Oncologist, 2022, v. 27, n. 4, p. e328, doi. 10.1093/oncolo/oyab041
- By:
- Publication type:
- Article
Depression, Anxiety, and Patterns of Mental Health Care Among Men With Prostate Cancer Receiving Androgen Deprivation Therapy.
- Published in:
- Oncologist, 2022, v. 27, n. 4, p. 314, doi. 10.1093/oncolo/oyab033
- By:
- Publication type:
- Article
Cetuximab and Irinotecan With or Without Bevacizumab in Refractory Metastatic Colorectal Cancer: BOND-3, an ACCRU Network Randomized Clinical Trial.
- Published in:
- Oncologist, 2022, v. 27, n. 4, p. 292, doi. 10.1093/oncolo/oyab025
- By:
- Publication type:
- Article
Survival According to Primary Tumor Location, Stage, and Treatment Patterns in Locoregional Gastroenteropancreatic High-grade Neuroendocrine Carcinomas.
- Published in:
- Oncologist, 2022, v. 27, n. 4, p. 299, doi. 10.1093/oncolo/oyab039
- By:
- Publication type:
- Article